Journalism in the Public Interest

Prescriber Checkup

Prescriber Checkup » RITUXAN



Rituxan (Rituximab) is a monoclonal antibody. It targets a specific protein on white blood cells that makes it easier for your immune system to find and destroy cancerous cells. It also relieves symptoms and slows the progression of Rheumatoid Arthritis. Source: Iodine  *

*This description is for related drug Rituximab

At a Glance: This Drug in 2014

Medicare Part D Claims

Rank: 1609 of 3362

Retail Cost

Rank: 490 of 3362


Rank: 1550 of 3362


Rank: 1803 of 3362

More info on related drug Rituximab »

Information courtesy of


of people say

it's worth it


of people say

it worked well

Use by state

State Patients Claims Cost
New York 359 1,085 $8.72M
California 383 1,021 $8.26M
Florida 168 437 $3.57M
Texas 185 420 $4.31M
New Jersey 83 178 $1.85M
Pennsylvania 44 105 $851K
Massachusetts 46 101 $961K
Georgia 23 71 $540K
Ohio 43 70 $919K
Illinois 17 64 $394K
Maryland 11 54 $356K
Connecticut 13 54 $367K
Louisiana 20 45 $521K
Colorado 11 44 $329K
Tennessee 11 37 $275K
Oklahoma 15 37 $647K
Missouri 13 37 $279K
Mississippi 11 35 $211K
Nevada 33 $277K
Michigan 22 $157K
New Mexico 20 $310K
North Carolina 11 19 $210K
Oregon 13 16 $101K
Virginia 16 $135K
Arizona 11 $217K
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. The data for 2014 includes more than 1.4 billion prescriptions written by more than 1.3 million doctors, nurses and other providers. This database lists about 428,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to and we will update your information. If you have other questions about this data, send a note to